A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase

Analytical Biochemistry

Volumn 403, Issue 1-2, 2010, Pages 52-62

  Lee, Jin Ching ^a   Tseng, Chin kai ^a   Chen, Kuan Jen ^a   Huang, Kuo Jung ^a   Lin, Chun Kuang ^a   Lin, Ying Ting ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatitis C virus; High throughput screening; Luciferase; RNA dependent RNA polymerase

Indexed keywords

CELL CULTURE; GENES; PLANTS (BOTANY); VIRUSES;

HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; IMIDAZOLE DERIVATIVES; INHIBITOR SCREENINGS; LUCIFERASE; REVERSE ORIENTATION; RNA-DEPENDENT RNA POLYMERASE; UNTRANSLATED REGIONS;

RNA;

2' METHYLCYTIDINE; CYCLOSPORIN A; DACTINOMYCIN; FIREFLY LUCIFERASE; IMIDAZOLE DERIVATIVE; NONSTRUCTURAL PROTEIN 5B; NUCLEOTIDE; PACLITAXEL; RENILLA LUCIFERIN 2 MONOOXYGENASE; RNA DIRECTED RNA POLYMERASE; WEDELOLACTONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LUCIFERASE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME ACTIVITY; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REPORTER GENE; VIRTUAL REALITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; ENZYMOLOGY; EVALUATION STUDY; GENETICS; HEPACIVIRUS; METABOLISM; PROCEDURES;

HEPATITIS C VIRUS; RENILLA LUCIFERASE;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; GENES, REPORTER; HEPACIVIRUS; HIGH-THROUGHPUT SCREENING ASSAYS; LUCIFERASES; RNA REPLICASE;

EID: 77953357109     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.04.004     Document Type: Article

References (52)

1. Williams R. Global challenges in liver disease. Hepatology 2006, 44:521-526.
2. Alter M.J. Epidemiology of hepatitis C. Hepatology 1997, 26:62S-65S.
3. Ferenci P. Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future. Minerva Gastroenterol. Dietol. 2006, 52:157-174.
4. Pawlotsky J.M. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006, 43:S207-220.
5. Schaefer M., Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr. Drug Abuse Rev. 2008, 1:177-187.
6. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
7. Yi M., Lemon S.M. 3' Nontranslated RNA signals required for replication of hepatitis C virus RNA. J. Virol. 2003, 77:3557-3568.
8. Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 2004, 39:5-19.
9. Kwong A.D., McNair L., Jacobson I., George S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 2008, 8:522-531.
10. Wang Y.K., Rigat K.L., Roberts S.B., Gao M. A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase. Anal. Biochem. 2006, 359:106-111.
11. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972-1974.
12. Heller T., Saito S., Auerbach J., Williams T., Moreen T.R., Jazwinski A., Cruz B., Jeurkar N., Sapp R., Luo G., Liang T.J. An in vitro model of hepatitis C virion production. Proc. Natl. Acad. Sci. USA 2005, 102:2579-2583.
13. Lee C.M., Hung C.H., Lu S.N., Wang J.H., Tung H.D., Huang W.S., Chen C.L., Chen W.J., Changchien C.S. Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan. Intervirology 2006, 49:76-81.
14. Whelan J.A., Russell N.B., Whelan M.A. A method for the absolute quantification of cDNA using real-time PCR. J. Immunol. Methods 2003, 278:261-269.
15. Pan K.L., Lee J.C., Sung H.W., Chang T.Y., Hsu J.T. Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection. Antimicrob. Agents Chemother. 2009, 53:4825-4834.
16. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73.
17. Weber P.C., Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 1999, 6:937-943.
18. Ago H., Adachi T., Yoshida A., Yamamoto M., Habuka N., Yatsunami K., Miyano M. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure (London, England; 1993) 1999, 7:1417-1426.
19. Halgren T.A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 20:720-729.
20. Halgren T.A. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 1999, 20:730-748.
21. Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model. 2003, 21:289-307.
22. D.S. LigandFit, Accelrys Software Inc., 10188 Telesis Court, Suite 100 San Diego, CA 92121, USA.
23. M.C. Company, Maybridge Chemical Company, The source of this database is the Maybridge Chemical Company (England), All compounds listed are available from Maybridge.
24. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
25. Schuster C., Isel C., Imbert I., Ehresmann C., Marquet R., Kieny M.P. Secondary structure of the 3' terminus of hepatitis C virus minus-strand RNA. J. Virol. 2002, 76:8058-8068.
26. Reigadas S., Ventura M., Sarih-Cottin L., Castroviejo M., Litvak S., Astier-Gin T. HCV RNA-dependent RNA polymerase replicates in vitro the 3' terminal region of the minus-strand viral RNA more efficiently than the 3' terminal region of the plus RNA. Eur. J. Biochem. 2001, 268:5857-5867.
27. Dahari H., Ribeiro R.M., Rice C.M., Perelson A.S. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J. Virol. 2007, 81:750-760.
28. Kaushik-Basu N., Bopda-Waffo A., Talele T.T., Basu A., Costa P.R., da Silva A.J., Sarafianos S.G., Noel F. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res. 2008, 36:1482-1496.
29. Clark J.L., Hollecker L., Mason J.C., Stuyver L.J., Tharnish P.M., Lostia S., McBrayer T.R., Schinazi R.F., Watanabe K.A., Otto M.J., Furman P.A., Stec W.J., Patterson S.E., Pankiewicz K.W. Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 2005, 48:5504-5508.
30. Yang F., Robotham J.M., Nelson H.B., Irsigler A., Kenworthy R., Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 2008, 82:5269-5278.
31. Qing M., Yang F., Zhang B., Zou G., Robida J.M., Yuan Z., Tang H., Shi P.Y. Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob. Agents Chemother. 2009, 53:3226-3235.
32. McCown M.F., Rajyaguru S., Le Pogam S., Ali S., Jiang W.R., Kang H., Symons J., Cammack N., Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 2008, 52:1604-1612.
33. Bassit L., Grier J., Bennett M., Schinazi R.F. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir. Chem. Chemother. 2008, 19:25-31.
34. Goto K., Watashi K., Murata T., Hishiki T., Hijikata M., Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun. 2006, 343:879-884.
35. Watashi K., Hijikata M., Hosaka M., Yamaji M., Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003, 38:1282-1288.
36. Antonysamy S.S., Aubol B., Blaney J., Browner M.F., Giannetti A.M., Harris S.F., Hébert N., Hendle J., Hopkins S., Jefferson E. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:2990-2995.
37. Kato N. Molecular virology of hepatitis C virus. Acta Med. Okayama 2001, 55:133-159.
38. Lee J.C., Yu M.C., Lien T.W., Chang C.F., Hsu J.T. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors. Assay Drug Dev. Technol. 2005, 3:385-392.
39. Lee J.C., Chang C.F., Chi Y.H., Hwang D.R., Hsu J.T. A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. J. Virol. Methods 2004, 116:27-33.
40. Iro M., Witteveldt J., Angus A.G., Woerz I., Kaul A., Bartenschlager R., Patel A.H. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antivir. Res. 2009, 83:148-155.
41. Hao W., Duggal R. High-throughput screening of HCV RNA replication inhibitors by means of a reporter replicon system. Methods Mol. Biol. 2009, 510:243-250.
42. King R.W., Zecher M., Jeffries M.W., Carroll D.R., Parisi J.M., Pasquinelli C. A cell-based model of HCV-negative-strand RNA replication utilizing a chimeric hepatitis C virus/reporter RNA template. Antivir. Chem. Chemother. 2002, 13:353-362.
43. Kong L.B., Ye L.B., Ye L., Timani K.A., Zheng Y., Liao Q.J., Li B.Z., Gao B. Establishment of stable HeLa cell lines expressing enzymatically active hepatitis C virus RNA polymerase. Arch. Virol. 2006, 151:361-367.
44. Kong L., Li S., Han X., Xiang Z., Fang X., Li B., Wang W., Zhong H., Gao J., Ye L. Inhibition of HCV RNA-dependent RNA polymerase activity by aqueous extract from Fructus Ligustri Lucidi. Virus Res. 2007, 128:9-17.
45. Fukushi S., Kojima S., Takai R., Hoshino F.B., Oka T., Takeda N., Katayama K., Kageyama T. Poly(A)- and primer-independent RNA polymerase of norovirus. J. Virol. 2004, 78:3889-3896.
46. Ferrari E., Wright-Minogue J., Fang J.W., Baroudy B.M., Lau J.Y., Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol. 1999, 73:1649-1654.
47. Ivanov A.V., Korovina A.N., Tunitskaya V.L., Kostyuk D.A., Rechinsky V.O., Kukhanova M.K., Kochetkov S.N. Development of the system ensuring a high-level expression of hepatitis C virus nonstructural NS5B and NS5A proteins. Protein Expr. Purif. 2006, 48:14-23.
48. Hao W., Herlihy K.J., Zhang N.J., Fuhrman S.A., Doan C., Patick A.K., Duggal R. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob. Agents Chemother. 2007, 51:95-102.
49. Kim J., Kim K.S., Kim D.E., Chong Y. Identification of novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening. Chem. Biol. Drug Des. 2008, 72:585-591.
50. Ryu K., Kim N.D., Choi S.I., Han C.K., Yoon J.H., No K.T., Kim K.H., Seong B.L. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorg. Med. Chem. 2009, 17:2975-2982.
51. Hirashima S., Suzuki T., Ishida T., Noji S., Yata S., Ando I., Komatsu M., Ikeda S., Hashimoto H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 2006, 49:4721-4736.
52. Vliegen I., Paeshuyse J., De Burghgraeve T., Lehman L.S., Paulson M., Shih I.H., Mabery E., Boddeker N., De Clercq E., Reiser H., Oare D., Lee W.A., Zhong W., Bondy S., Purstinger G., Neyts J. Substituted imidazopyridines as potent inhibitors of HCV replication. J. Hepatol. 2009, 50:999-1009.